Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Allergan released its third-quarter financials, with mixed results and plans to make fairly major changes.
Shares of Halyard Health are up more than 12 percent after the company announced it was selling its S&IP business to Owens & Minor for $710M.
The Crestwood, KY-based company plans to raise $150M by offering 10.7 million shares at a price range of $13 to $15.
Investors and analysts are wondering if the company should buy a biotech to bolster its pipeline and bottom line.
Fosun Pharma said it would buy Tridem Pharma S.A.S. for $73M, in a move to expand its market share in Europe and Africa.
As part of consolidation program, Shire is looking to sell a manufacturing facility in Milford, MA that it gained through its 2015 acquisition of Baxalta.
Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9B acquisition of Advanced Accelerator Applications.
Merck released its third-quarter financial results today, and along with it a hint--just a hint--that there might be some M&A deals in the future.
Siemens AG is looking to take its Healthineers unit public.
Shares of Neos Therapeutics have soared more than 38 percent this morning after PDL BioPharma announced its intention to acquire the company in an all-cash deal that could total about $287M.